AA
ABVX

AlphaCentric Advisors’s Abivax ABVX Stock Holding History

AlphaCentric Advisors’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$685K Buy
5,141
+1,717
+50% +$194K 0.58% 54
2026
Q1 		$381K Buy
+3,424
New +$405K 0.38% 91
2024
Q1 		– Sell
-267,500
Closed -$2.86M – 229
2023
Q4 		$2.86M Buy
+267,500
New +$2.73M 1.92% 12

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

AlphaCentric Advisors's ABVX Position: Q2 2026 in Review

AlphaCentric Advisors increased its Abivax (ABVX) stake by 50% in Q2 2026, buying an estimated $194K and bringing the position to 5,141 shares worth $685K. The position accounts for 0.58% of the portfolio, ranked #54.

AlphaCentric Advisors first reported a position in ABVX in Q4 2023 and has held it in 3 quarters since. The position peaked at $2.86M in Q4 2023. 302 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • AlphaCentric Advisors held 5,141 shares of Abivax worth $685K as of Q2 2026.
  • AlphaCentric Advisors bought 1,717 Abivax shares in Q2 2026, an estimated $194K.
  • Abivax made up 0.58% of AlphaCentric Advisors's portfolio in Q2 2026, its #54 holding.
  • AlphaCentric Advisors first reported a position in Abivax in Q4 2023 and has held it in 3 quarters since.
  • AlphaCentric Advisors's Abivax position peaked at $2.86M in Q4 2023.
  • 302 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on AlphaCentric Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.